Cargando…

Dynamics of hepatic steatosis resolution and changes in gut microbiome with weight loss in nonalcoholic fatty liver disease

BACKGROUND: Weight loss is recommended as the primary treatment for nonalcoholic fatty liver disease (NAFLD). However, the magnitude and velocity of hepatic steatosis resolution with weight loss is unclear, making it difficult to counsel patients seeking weight loss for treatment of NAFLD. The aim o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Behari, Jaideep, Graham, Lisa, Wang, Renwei, Schirda, Claudiu, Borhani, Amir A., Methé, Barbara A., Li, Kelvin, Morris, Alison, Luu, Hung N., Palmieri, Sabrina, Yuan, Jian‐Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019274/ https://www.ncbi.nlm.nih.gov/pubmed/33841891 http://dx.doi.org/10.1002/osp4.476

Ejemplares similares

Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis
por: Behari, Jaideep, et al.
Publicado: (2023)

Neutrophil‐lymphocyte ratio in relation to risk of hepatocellular carcinoma in patients with non‐alcoholic fatty liver disease
por: Thomas, Claire E., et al.
Publicado: (2022)

Does Nonalcoholic Pancreatic Steatosis Always Correlate with Nonalcoholic Fatty Liver Disease?
por: Ulasoglu, Celal, et al.
Publicado: (2021)

Weight Loss in Nonalcoholic Fatty Liver Disease Patients in an Ambulatory Care Setting Is Largely Unsuccessful but Correlates with Frequency of Clinic Visits
por: Dudekula, Anwar, et al.
Publicado: (2014)

Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis
por: Koo, Seung-Hoi
Publicado: (2013)

Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease
por: Pirmoazen, Amir M., et al.
Publicado: (2020)

Nonalcoholic Fatty Liver Disease: Noninvasive Methods of Diagnosing Hepatic Steatosis
por: AlShaalan, Rasha, et al.
Publicado: (2015)

Herbicide Widespread: The Effects of Pethoxamid on Nonalcoholic Fatty Liver Steatosis In Vitro
por: Pirozzi, Anna Virginia Adriana, et al.
Publicado: (2020)

Hepatic Steatosis in Infancy: The Beginning of Pediatric Nonalcoholic Fatty Liver Disease?
por: McNelis, Kera, et al.
Publicado: (2021)

Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
por: Lee, Hyo Young, et al.
Publicado: (2019)

Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
por: Lee, Na Young, et al.
Publicado: (2021)

Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis
por: Li, Jinwang, et al.
Publicado: (2021)

Gut microbiome profiles associated with steatosis severity in metabolic associated fatty liver disease
por: Dong, Tien S., et al.
Publicado: (2021)

Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats
por: Fukunishi, Shinya, et al.
Publicado: (2014)

Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease
por: Dai, Yi-Ning, et al.
Publicado: (2022)

Discrepancies between Nonalcoholic and Metabolic-associated Fatty Liver Disease by Multiple Steatosis Assessment
por: Shao, Congxiang, et al.
Publicado: (2022)

Change in skeletal muscle mass is associated with hepatic steatosis in nonalcoholic fatty liver disease
por: Jo, Ik Hyun, et al.
Publicado: (2023)

Impact of Hepatic Steatosis on Resting Metabolic Rate and Metabolic Adaptation in Response to Intentional Weight Loss
por: Rachakonda, Vikrant P., et al.
Publicado: (2019)

Reduced Serum Sphingolipids Constitute a Molecular Signature of Malnutrition in Hospitalized Patients With Decompensated Cirrhosis
por: Rachakonda, Vikrant, et al.
Publicado: (2019)

Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice
por: Rom, Oren, et al.
Publicado: (2019)

The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease
por: Roychowdhury, Sanjoy, et al.
Publicado: (2018)

Serum Leptin Is a Biomarker of Malnutrition in Decompensated Cirrhosis
por: Rachakonda, Vikrant, et al.
Publicado: (2016)

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
por: Ahn, Sang Bong
Publicado: (2023)

Cyanotoxins Increase Cytotoxicity and Promote Nonalcoholic Fatty Liver Disease Progression by Enhancing Cell Steatosis
por: Niture, Suryakant, et al.
Publicado: (2023)

Analyses of the Stability and Core Taxonomic Memberships of the Human Microbiome
por: Li, Kelvin, et al.
Publicado: (2013)

Characterization of gut microbiome composition in Iranian patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Abdollahiyan, Sara, et al.
Publicado: (2023)

Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease
por: Luukkonen, Panu K., et al.
Publicado: (2020)

Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis
por: Allende, Daniela S, et al.
Publicado: (2021)

Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Han, Eugene, et al.
Publicado: (2021)

Hyperferritinemia Correlates to Metabolic Dysregulation and Steatosis in Chinese Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients
por: Wang, Qingling, et al.
Publicado: (2022)

Andrographolide ameliorates hepatic steatosis by suppressing FATP2-mediated fatty acid uptake in mice with nonalcoholic fatty liver disease
por: Ran, Li-Sha, et al.
Publicado: (2022)

Analyses of the Microbial Diversity across the Human Microbiome
por: Li, Kelvin, et al.
Publicado: (2012)

Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome
por: Castillo-Castro, Carolina, et al.
Publicado: (2021)

Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis
por: Ganbold, Munkhzul, et al.
Publicado: (2019)

Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice
por: Takahara, Ikuko, et al.
Publicado: (2017)

Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease
por: Ahn, Jem Ma, et al.
Publicado: (2016)

Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease
por: Mukai, Takako, et al.
Publicado: (2017)

Therapeutic Effects of Garlic on Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Patients: A Randomized Clinical Trial
por: Soleimani, Davood, et al.
Publicado: (2020)

The p66shc-mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease
por: Zhang, Jing, et al.
Publicado: (2020)

Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease
por: Nadinskaia, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6qp1nd5htsfl2151fhmc1q05no